Belite Bio (BLTE) Common Equity (2020 - 2026)
Belite Bio (BLTE) posted quarterly Common Equity of $795.8 million for Q1 2026, up 403.44% year-over-year from $158.1 million in Q1 2025, and up 3.28% quarter-over-quarter from $770.5 million in Q4 2025.
Belite Bio (BLTE) Common Equity (2020 - 2026) Analysis & Trends
Belite Bio's Common Equity history runs 7 years deep, the most recent figure standing at $795.8 million for Q1 2026.
- In Q1 2026, Common Equity rose 403.44% year-over-year to $795.8 million; the TTM figure through Mar 2026 stood at $795.8 million (up 403.44% YoY), while the FY2025 annual figure was $770.5 million, up 428.38% from the prior year.
- Common Equity for Q1 2026 stood at $795.8 million, up from $770.5 million in the prior quarter.
- The five-year high for Common Equity was $795.8 million in Q1 2026, with the low at $35.2 million in Q1 2023.
- The 5-year median for Common Equity is $113.4 million (2024), against an average of $206.6 million.
- Peak annual rise in Common Equity reached 428.38% in 2025, while the deepest fall reached 30.8% in 2025.
- Belite Bio's Common Equity stood at $41.5 million in 2022, then jumped by 117.9% to $90.4 million in 2023, then surged by 61.25% to $145.8 million in 2024, then surged by 428.38% to $770.5 million in 2025, then climbed by 3.28% to $795.8 million in 2026.
- Business Quant data shows BLTE's Common Equity at $795.8 million in Q1 2026, $770.5 million in Q4 2025, and $274.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Belite Bio | 6.40 Bn | 6.40 Bn | - | 795.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 795.79 Mn |
| Dec 31, 2025 | 770.49 Mn |
| Sep 30, 2025 | 274.08 Mn |
| Jun 30, 2025 | 149.89 Mn |
| Mar 31, 2025 | 158.07 Mn |
| Dec 31, 2024 | 145.82 Mn |
| Sep 30, 2024 | 112.20 Mn |
| Jun 30, 2024 | 114.59 Mn |
| Mar 31, 2024 | 96.47 Mn |
| Dec 31, 2023 | 90.43 Mn |
| Sep 30, 2023 | 52.79 Mn |
| Jun 30, 2023 | 55.72 Mn |
| Mar 31, 2023 | 35.17 Mn |
| Dec 31, 2022 | 41.50 Mn |
| Dec 31, 2021 | -15.09 Mn |
| Dec 31, 2020 | -7.04 Mn |